5 Healthcare Stocks to Watch in Light of Biden’s ‘60 Minutes’ Interview

3. BioNTech SE (NASDAQ:BNTX)

Number of Hedge Fund Holders: 26

Year-to-Date Performance: -42.29%

BioNTech SE (NASDAQ:BNTX) is another biotech company on our list, developing immunotherapies for cancer and other infectious diseases, alongside vaccines. The company is based in Mainz, Germany.

A Market Perform rating was placed on BioNTech SE (NASDAQ:BNTX) shares on August 17, by analyst Yaron Werber at Cowen. The analyst also placed a $177 price target on the stock.

The day after Biden’s 60 Minutes interview, BioNTech SE (NASDAQ:BNTX) fell 9%. The stock has fallen 42.29% year-to-date and its EPS growth rate over the next three to five years stands at -40.41%.

BioNTech SE (NASDAQ:BNTX) was found among the 13F holdings of 26 funds in the second quarter. Their total stake value was $380 million.

Baron Funds, an asset management firm, mentioned BioNTech SE (NASDAQ:BNTX) in its third quarter 2021 investor letter. Here’s what the firm said:

“BioNTech SE is a leader in the emerging field of mRNA drugs, with additional programs in engineered cell therapies, antibodies, and immunomodulators. Shares performed well for the quarter. The COVID-19 vaccine rollout continues with the addition of a booster shot, and we believe the pandemic has been a strong proof point of the speed and efficacy of the mRNA platform. Beyond vaccines, we think BioNTech has potential to disrupt the biopharmaceutical space with a pipeline spanning oncology, infectious diseases, and rare diseases.”